Ultragenyx Pharmaceutical

Nachrichten

Ultragenyx Pharmaceutical Aktie

Aktie

ISIN: US90400D1081 WKN: A1XCY0 SYM: UP0 Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

20,810

EUR

+0,05 %

+0,010 EUR

Letzter Kurs 18:44:54 Tradegate

Ultragenyx Pharmaceutical Aktie kaufen

Geldkurs

20:04:56

20,830

EUR

770 STK

Briefkurs

20:04:56

21,280

EUR

760 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Mo-Fr von 07:30 bis 23:00 Uhr
Neu: Samstag von 14:00 bis 19:00 Uhr

Nachrichten zu Ultragenyx Pharmaceutical

Neueste Meldungen

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 Englische Nachricht

RARE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE Englische Nachricht

Artikel in Nachrichten zu Ultragenyx Pharmaceutical

Neueste
Meistgelesene

RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 06.04.26 · Business Wire (engl.)
RARE DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 05.04.26 · newsfile
RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 05.04.26 · newsfile
RARE DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 04.04.26 · newsfile
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE 04.04.26 · Business Wire (engl.)
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights 03.04.26 · Business Wire (engl.)
RARE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 03.04.26 · newsfile
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) 02.04.26 · globenewswire
RARE DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 02.04.26 · newsfile
RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 01.04.26 · newsfile
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 31.03.26 · newsfile
NASDAQ: RARE CLASS ACTION NOTICE: Berger Montague Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire About a Securities Fraud Class Action 30.03.26 · newsfile
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy 30.03.26 · globenewswire
ULTRAGENYX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 30.03.26 · newsfile
ULTRAGENYX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 29.03.26 · newsfile
ULTRAGENYX DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 27.03.26 · newsfile
RARE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 27.03.26 · newsfile
ULTRAGENYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE 26.03.26 · newsfile
RARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 26.03.26 · newsfile
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit 25.03.26 · Business Wire (engl.)
RARE DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE 25.03.26 · newsfile
RARE DEADLINE NOTICE: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE 24.03.26 · newsfile
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 23.03.26 · newsfile
SHAREHOLDER ALERT: Berger Montague Reminds Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Class Action Lawsuit Deadline 23.03.26 · newsfile
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 20.03.26 · globenewswire

1
2

30 Tage
6 Monate

RARE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 06.04.26 · newsfile · 140 Leser
ULTRAGENYX DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 27.03.26 · newsfile · 132 Leser
RARE DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RARE 18.03.26 · newsfile · 132 Leser
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE 04.04.26 · Business Wire (engl.) · 128 Leser
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit 25.03.26 · Business Wire (engl.) · 128 Leser
RARE DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 05.04.26 · newsfile · 124 Leser
RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 05.04.26 · newsfile · 124 Leser
RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE 01.04.26 · newsfile · 120 Leser
NASDAQ: RARE CLASS ACTION NOTICE: Berger Montague Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire About a Securities Fraud Class Action 30.03.26 · newsfile · 120 Leser
RARE DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE 25.03.26 · newsfile · 120 Leser

Silber, Dynavax Technologies & Co. – Tops & Flops der Community am Nachmittag 29.12.25 · Markt Bote · 1972 Leser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies \| DelveInsight 03.12.25 · PR Newswire (engl.) · 360 Leser
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta 29.12.25 · globenewswire · 204 Leser
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update 04.11.25 · globenewswire · 176 Leser
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE) 14.01.26 · newsfile · 176 Leser
Investigation Opened on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Shareholders - Contact Levi & Korsinsky 19.01.26 · newsfile · 168 Leser
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups 30.10.25 · globenewswire · 164 Leser
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces 06.02.26 · Business Wire (engl.) · 160 Leser
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) 30.12.25 · globenewswire · 156 Leser
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE 17.02.26 · newsfile · 156 Leser

Ultragenyx Pharmaceutical News

Ultragenyx Pharmaceutical News: Auf dieser Seite finden Sie alle Ultragenyx Pharmaceutical News und Nachrichten zur Ultragenyx Pharmaceutical Aktie. Dies beinhaltet die Agenturmeldungen auf wallstreet-online.de, aber auch Ultragenyx Pharmaceutical News von einer Vielzahl an Gastautoren, Partnern und Analysten.